Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment
about
The macrophages in rheumatic diseasesImmunopathology of synovitis: from histology to molecular pathwaysCellular targeting in autoimmunityOptimal management of dactylitis in patients with psoriatic arthritisNew pharmacological strategies in rheumatic diseasesSanguinaria canadensis: Traditional Medicine, Phytochemical Composition, Biological Activities and Current UsesChange in CD3 positive T-cell expression in psoriatic arthritis synovium correlates with change in DAS28 and magnetic resonance imaging synovitis scores following initiation of biologic therapy--a single centre, open-label study.Weight loss and achievement of minimal disease activity in patients with psoriatic arthritis starting treatment with tumour necrosis factor α blockers.Abatacept reduces synovial regulatory T-cell expression in patients with psoriatic arthritis.Interleukin-18 as an in vivo mediator of monocyte recruitment in rodent models of rheumatoid arthritisDownregulation of immunoglobulin-like transcript-4 (ILT4) in patients with psoriatic arthritis.The Th17 axis in psoriatic disease: pathogenetic and therapeutic implications.Synovial Tissue Response to Treatment with TNF Blockers in Peripheral SpondyloarthritisPreclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis.Psoriatic arthritis: an update.Markers of inflammation and bone remodelling associated with improvement in clinical response measures in psoriatic arthritis patients treated with golimumab.Hepatic steatosis, carotid plaques and achieving MDA in psoriatic arthritis patients starting TNF-α blockers treatment: a prospective study.Interleukin-18 as a potential therapeutic target in chronic autoimmune/inflammatory conditions.A prospective, randomised, placebo-controlled study to identify biomarkers associated with active treatment in psoriatic arthritis: effects of adalimumab treatment on synovial tissueAbatacept in psoriatic arthritis: Case report and short review.Psoriatic arthritis: from pathogenesis to therapy.The biological and clinical importance of the 'new generation' cytokines in rheumatic diseasesUtility of synovial biopsy.Synovitis in psoriatic arthritis: immunohistochemistry, comparisons with rheumatoid arthritis, and effects of therapy.Why is biologic therapy useful in spondyloarthritis? Knowledge from synovial immunopathologic studies of spondyloarthritis.Advances in the genetics of spondyloarthritis and clinical implications.Psoriatic arthritis: current therapy and future directions.Ustekinumab for the treatment of psoriatic arthritis.Lipid profile changes in patients with rheumatic diseases receiving a treatment with TNF-α blockers: a meta-analysis of prospective studies.Can suppression of inflammation by anti-TNF prevent progression of subclinical atherosclerosis in inflammatory arthritis?The Efficacy and Safety of Clazakizumab, an Anti-Interleukin-6 Monoclonal Antibody, in a Phase IIb Study of Adults With Active Psoriatic Arthritis.Psoriatic arthritis under a proteomic spotlight: application of novel technologies to advance diagnosis and management.Progress in understanding and utilizing TNF-α inhibition for the treatment of psoriatic arthritis.Tumor necrosis factor inhibitors in psoriatic arthritis.Psoriatic arthritis and psoriasis: differential diagnosis.Targeted therapies: what they teach us about the pathogenesis of psoriasis and psoriatic arthritis.Up-regulation of CD64-expressing monocytes with impaired FcγR function reflects disease activity in polyarticular psoriatic arthritis.Differential Effects of Inflammation on Bone and Response to Biologics in Rheumatoid Arthritis and Spondyloarthritis.Quantitative imaging by pixel-based contrast-enhanced ultrasound reveals a linear relationship between synovial vascular perfusion and the recruitment of pathogenic IL-17A-F+IL-23+ CD161+ CD4+ T helper cells in psoriatic arthritis joints.The pharmacodynamic impact of apremilast, an oral phosphodiesterase 4 inhibitor, on circulating levels of inflammatory biomarkers in patients with psoriatic arthritis: substudy results from a phase III, randomized, placebo-controlled trial (PALACE 1
P2860
Q26765275-6FB0B558-F7D4-4C9F-A852-42FDA4695A5BQ26781647-E8B775A6-A084-4689-B54F-D349EC868140Q26824580-191BDBAE-F3DB-4577-9144-FE9FED5A2500Q28072557-91CD7D78-7DAD-4CBC-9F2C-D6760FC99E3AQ28073763-2DF5F537-0823-4B8A-8CF7-F80171A7A9F2Q28077612-0DED5739-55C4-4E36-B630-8080C0DD574DQ33390403-A990B52D-2364-40BB-8875-31B47B785558Q33659058-239916FF-3944-4B32-BA16-325CCF08499DQ33876826-B23A6FD5-18EE-4EA8-98F3-3FA2A445E2E3Q34027630-CAD42DB7-F812-4943-A7C3-3360D75BF5AEQ35133638-C988D7B3-14F1-4353-BA2F-C20DCA1BC831Q35308947-F4B708AC-F9A7-4CCF-8368-AB3B578A704EQ35687019-D350B809-3839-4936-B92A-7A88B15BE5FBQ36150157-44FFDC77-E04D-4F63-887D-D7C00A1C0A5DQ36417852-802F23D1-E4E4-4C2C-86D1-B14BD4E2FFC1Q36550827-F9EDF123-1341-41BC-900C-F2D8836C3548Q36633179-C63A8E28-7D3E-4296-90DF-325D3090368FQ36675441-1D153E9B-2CF0-4197-A357-99101EC8C2BFQ37245184-ED02545A-135C-4F8D-8B43-470281FBCEE4Q37369635-7A4199CC-D07F-450E-875A-A09187FFCC71Q37397676-2BDF7315-567E-4DD9-A17B-F01356053F3DQ37516563-54A581B8-2C25-446D-AF66-67BDCCCF5C9AQ37642085-B3267787-98A6-4C65-87D4-08591877536EQ37866683-F16C92B9-1324-4021-AD56-E1841A15FEC4Q38068590-2ABB42B6-0E03-4CE1-B88F-2021A733B8A7Q38114840-99B052AF-64FE-423F-B147-378CF268597DQ38118343-7DF25D49-832A-444C-AD73-2C7FA12E4B2FQ38177336-22B0735F-6FB2-4C59-AB8A-F3D2ECBBBFCFQ38181566-018387B9-5465-46C6-9CA4-4B50F49510DDQ38185646-EF5BA79E-BC75-47D8-A6EB-A5DD7AC90E95Q38393840-5799728F-1E55-4D0C-AE0B-16639F1274E3Q38431361-25197547-748A-42CE-9084-B90817DC13FEQ38630548-13B9B574-3277-4D3D-9617-D996D104BB1FQ38685543-4B06E859-ED58-47E9-AD83-1FCB63DB9699Q38828427-44696416-3893-4A16-9CDD-41CF251DAAA9Q38969036-F2508A03-FCA7-4F15-974C-28F87BCA50D9Q38994737-4020023B-F246-4F84-8E79-22907BEB433FQ38998373-BFC36673-C341-4109-81DB-DE6EFF83CBA2Q39084926-D4FF9003-A3EA-4D63-BF95-7CD667EE5759Q40204659-948A63E2-9A34-45FE-BCAC-954B52773AF3
P2860
Detailed analysis of the cell infiltrate and the expression of mediators of synovial inflammation and joint destruction in the synovium of patients with psoriatic arthritis: implications for treatment
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Detailed analysis of the cell ...... is: implications for treatment
@ast
Detailed analysis of the cell ...... is: implications for treatment
@en
type
label
Detailed analysis of the cell ...... is: implications for treatment
@ast
Detailed analysis of the cell ...... is: implications for treatment
@en
prefLabel
Detailed analysis of the cell ...... is: implications for treatment
@ast
Detailed analysis of the cell ...... is: implications for treatment
@en
P2093
P2860
P356
P1476
Detailed analysis of the cell ...... is: implications for treatment
@en
P2093
Dijkmans BA
Reinders-Blankert P
van Kuijk AW
P2860
P304
P356
10.1136/ARD.2005.050963
P407
P577
2006-05-25T00:00:00Z